Mind the gap – Managing tuberculosis across the disease spectrum
Open Access
- 23 March 2022
- journal article
- review article
- Published by Elsevier in EBioMedicine
- Vol. 78, 103928
Abstract
No abstract availableKeywords
Funding Information
- European Research Council (757699)
- Australian Respiratory Council
- Medical Research Council (MR/V00476X/1)
- Medical Research Council (MC_UU_00004/04)
This publication has 65 references indexed in Scilit:
- The spectrum of latent tuberculosis: rethinking the biology and intervention strategiesNature Reviews Microbiology, 2009
- Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture ConversionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection: Is It Safe?American Journal of Respiratory and Critical Care Medicine, 2003
- Regimens of less than six months for treating tuberculosisCochrane Database of Systematic Reviews, 1999
- Isoniazid for preventing tuberculosis in non-HIV infected personsCochrane Database of Systematic Reviews, 1999
- CT of pulmonary tuberculosisSeminars in Ultrasound, CT and MRI, 1995
- Smear-negative, Culture-positive Pulmonary Tuberculosis: Six-month Chemotherapy with Isoniazid and RifampinAmerican Review of Respiratory Disease, 1990
- Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: The results up to 30 monthsTubercle, 1981
- Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council InvestigationBMJ, 1948
- Mass Radiography: A new Weapon against Tuberculosis1944